EUVIMEDEUVIMED entdecken
Crossref

Humanizing meropenem dosage regimens by co-administration of cilastatin in an immunocompetent mouse bloodstream infection model of Acinetobacter baumannii based on a novel quantitative matching framework

Yuanyuan Jiao, Jun Yan, Dhruvitkumar S Sutaria, Michael Vicchiarelli, Peggy Lu, Xindi Shan, Yinzhi Lang, Taehyung Kim, Zeferino Reyna, Brad Spellberg iD, Robert A Bonomo, George L Drusano und 3 weitere

Journal of Antimicrobial Chemotherapy · 04.08.2026 · 81 (9)

DOI: 10.1093/jac/dkag274 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Antimicrobial Chemotherapy, online erschienen am 14.08.2026. Verfasst von Yuanyuan Jiao und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacotherapy and Translational Research, College of Pharmacy, University of Florida, Orlando, FL, USA. Hauptthemen laut MEDLINE: Meropenem, Cilastatin, Acinetobacter Infections, Acinetobacter baumannii. Die Arbeit nennt 49 Literaturangaben. Gefördert von: U.S. Food and Drug Administration (FDA), VA, Department of Veterans Affairs.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Meropenem is commonly used to treat serious bacterial infections, but its short half-life in mice impedes achieving human-like drug exposure profiles. This study aimed to create humanized meropenem dosage regimens in immunocompetent mice with bloodstream infections by Acinetobacter baumannii.

Methods

Cilastatin was administered to prolong the meropenem half-life in mice and match the concentration–time profiles of meropenem in patients. An integrated population pharmacokinetic model was developed to characterize the concentration-dependent inhibition of meropenem clearance by cilastatin. Murine dosage regimens were humanized based on a novel matching framework. Firstly, meropenem plasma concentrations in mice should remain within the 5th to 95th percentiles of plasma concentrations for meropenem monotherapy in critically ill patients. Secondly, the free-time-above-MIC versus MIC profiles of meropenem in mice should match those in patients.

Results

The meropenem half-life in mice increased from 22.2 min without cilastatin to 57.7 min at high cilastatin concentrations. Cilastatin inhibited the meropenem clearance half-maximally at 0.230 mg/L. Subcutaneous doses of 53/10 mg/kg meropenem/cilastatin at 0 h and 26/10 mg/kg at 3 h in mice, both repeated every 8 h, resulted in well-matched pharmacokinetic profiles to those of 2 g meropenem infusions over 30 min at the same dosing interval in patients.

Conclusions

Co-administration of cilastatin substantially prolonged the meropenem half-life in mice and enabled humanized meropenem dosage regimens with six doses per day to stay within the 5th and 95th percentiles of plasma concentrations in patients. This novel framework to humanize murine dosage regimens is based on quantitative matching criteria and supports translational research by achieving clinically relevant exposure profiles in mice.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MeropenemCilastatinAcinetobacter InfectionsAcinetobacter baumanniiAnti-Bacterial AgentsBacteremiaAnimalsMiceDisease Models, AnimalMicrobial Sensitivity TestsHumansHalf-LifeMaleThienamycinsFemalePlasma

Substanzen

MeropenemCilastatinAnti-Bacterial AgentsThienamycins

Autor:innen und Institutionen

  • Department of Pharmacotherapy and Translational Research, College of Pharmacy, University of Florida, Orlando, FL, USA.
  • Department of Immunology and Immune Therapeutics, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.
  • Institute for Therapeutic Innovation, College of Medicine, University of Florida, Orlando, FL, USA.
  • Department of Pharmacy and Pharmaceutical Sciences, St. Jude Children's Research Hospital, 262 Danny Thomas Pl, Memphis, TN 38105, USA.
  • Department of Pharmaceutical Sciences, University of Tennessee Health Science Center, Memphis, TN, USA.
  • Department of Medicine, Los Angeles General Medical Center, Los Angeles, CA, USA.

ORCID-Profile: Brad Spellberg, Arnold Louie, Brian M Luna, Jürgen B Bulitta

Förderung

  • U.S. Food and Drug Administration (FDA)
  • VA
  • Department of Veterans Affairs

Zitieren

APA

Jiao, Y., Yan, J., Sutaria, D. S., Vicchiarelli, M., Lu, P., Shan, X., Lang, Y., Kim, T., Reyna, Z., Spellberg, B., Bonomo, R. A., Drusano, G. L., Louie, A., Luna, B. M., & Bulitta, J. B. (2026). Humanizing meropenem dosage regimens by co-administration of cilastatin in an immunocompetent mouse bloodstream infection model of Acinetobacter baumannii based on a novel quantitative matching framework. Journal of Antimicrobial Chemotherapy, 81(9). https://doi.org/10.1093/jac/dkag274

Vancouver

Jiao Y, Yan J, Sutaria DS, Vicchiarelli M, Lu P, Shan X, et al. Humanizing meropenem dosage regimens by co-administration of cilastatin in an immunocompetent mouse bloodstream infection model of Acinetobacter baumannii based on a novel quantitative matching framework. Journal of Antimicrobial Chemotherapy. 2026;81(9). doi:10.1093/jac/dkag274

BibTeX
@article{Jiao2026,
  author = {Jiao, Yuanyuan and Yan, Jun and Sutaria, Dhruvitkumar S and Vicchiarelli, Michael and Lu, Peggy and Shan, Xindi and Lang, Yinzhi and Kim, Taehyung and Reyna, Zeferino and Spellberg, Brad and Bonomo, Robert A and Drusano, George L and Louie, Arnold and Luna, Brian M and Bulitta, Jürgen B},
  title = {Humanizing meropenem dosage regimens by co-administration of cilastatin in an immunocompetent mouse bloodstream infection model of Acinetobacter baumannii based on a novel quantitative matching framework},
  journal = {Journal of Antimicrobial Chemotherapy},
  year = {2026},
  volume = {81},
  number = {9},
  doi = {10.1093/jac/dkag274}
}
Kostenlos starten →